Regeneron Pharmaceuticals (NASDAQ:REGN) and Celldex Therapeutics (NASDAQ:CLDX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.
Analyst Ratings
This is a summary of current recommendations for Regeneron Pharmaceuticals and Celldex Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
|---|
| Regeneron Pharmaceuticals | 0 | 5 | 14 | 0 | 2.74 |
| Celldex Therapeutics | 0 | 0 | 3 | 0 | 3.00 |
Regeneron Pharmaceuticals presently has a consensus price target of $656.3810, indicating a potential upside of 27.05%. Celldex Therapeutics has a consensus price target of $35.50, indicating a potential upside of 31.04%. Given Celldex Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Celldex Therapeutics is more favorable than Regeneron Pharmaceuticals.
Risk & Volatility
Regeneron Pharmaceuticals has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500. Comparatively, Celldex Therapeutics has a beta of 2.96, indicating that its share price is 196% more volatile than the S&P 500.
Profitability
This table compares Regeneron Pharmaceuticals and Celldex Therapeutics' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
|---|
| Regeneron Pharmaceuticals | 38.28% | 28.97% | 20.11% |
| Celldex Therapeutics | -1,069.42% | -30.93% | -26.55% |
Valuation and Earnings
This table compares Regeneron Pharmaceuticals and Celldex Therapeutics' revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
|---|
| Regeneron Pharmaceuticals | $7.86 billion | 7.04 | $2.12 billion | $21.47 | 24.06 |
| Celldex Therapeutics | $3.57 million | 300.61 | $-50,880,000.00 | ($3.28) | -8.26 |
Regeneron Pharmaceuticals has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
85.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 80.2% of Celldex Therapeutics shares are owned by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are owned by company insiders. Comparatively, 2.4% of Celldex Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Regeneron Pharmaceuticals beats Celldex Therapeutics on 10 of the 14 factors compared between the two stocks.
